Northwestern University professor Hande Ozdinler is hoping to change how ALS is treated, saying the disease is too complex ...
Amyotrophic lateral sclerosis may involve an autoimmune component — a finding that could reshape treatment strategies and ...
“Blessed are the peacemakers,” Trump wrote on social media. Well, they sure are, Mr. President, and now that you have brought ...
Neurizon is gearing up to begin its HEALEY ALS platform trial later this year after the FDA lifted a clinical hold on its ...
The ASX healthcare sector rose this week, with Morgans' Scott Power noting momentum is returning to the sector.
Stockhead on MSN
On track: Analysts hail FDA lift as turning point for Neurizon’s ALS therapy ambitions
Analysts have reacted positively to news that the US Food and Drug Administration (FDA) has lifted the clinical hold on ...
Eikonizo Therapeutics, a biopharmaceutical company developing disease-modifying therapies to improve the lives of people impacted by neurodegenerative and cardiorenal diseases, today announced the ...
Neurosense Therapeutics Ltd. ( ($NRSN) ) has issued an update. On October 6, 2025, NeuroSense Therapeutics Ltd. announced that its drug candidate ...
5d
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel ...
Stockhead on MSN
Health Check: Neurizon free to advance motor neurone disease trial after FDA lifts ‘clinical hold’
Neurizon Therapeutics is free to advance the next clinical trial of its candidate to treat amyotrophic lateral sclerosis (ALS ...
Explore the challenges of CNS drug development for neurodegenerative diseases and the complexity of measuring disease ...
In celebration of National Teachers’ Month, the Provincial Government of La Union (PGLU) reaffirmed its commitment to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback